CVS Health Corporation $CVS Stock Position Lowered by Capital City Trust Co. FL

Capital City Trust Co. FL lessened its position in CVS Health Corporation (NYSE:CVS) by 20.7% in the 2nd quarter, Holdings Channel reports. The fund owned 3,294 shares of the pharmacy operator’s stock after selling 858 shares during the period. Capital City Trust Co. FL’s holdings in CVS Health were worth $227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Clarius Group LLC lifted its position in CVS Health by 13.1% in the 2nd quarter. Clarius Group LLC now owns 3,611 shares of the pharmacy operator’s stock worth $249,000 after buying an additional 418 shares in the last quarter. QRG Capital Management Inc. lifted its position in CVS Health by 173.9% in the 2nd quarter. QRG Capital Management Inc. now owns 92,896 shares of the pharmacy operator’s stock worth $6,408,000 after buying an additional 58,984 shares in the last quarter. Boyar Asset Management Inc. lifted its position in CVS Health by 1.9% in the 2nd quarter. Boyar Asset Management Inc. now owns 18,779 shares of the pharmacy operator’s stock worth $1,295,000 after buying an additional 345 shares in the last quarter. Stock Yards Bank & Trust Co. lifted its position in CVS Health by 33.2% in the 2nd quarter. Stock Yards Bank & Trust Co. now owns 34,955 shares of the pharmacy operator’s stock worth $2,411,000 after buying an additional 8,716 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its position in CVS Health by 266.9% in the 2nd quarter. HighMark Wealth Management LLC now owns 1,897 shares of the pharmacy operator’s stock worth $131,000 after buying an additional 1,380 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS opened at $77.51 on Friday. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $79.20. The firm’s fifty day simple moving average is $70.71 and its 200 day simple moving average is $67.33. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $98.31 billion, a PE ratio of 21.65, a PEG ratio of 0.85 and a beta of 0.60.

CVS Health (NYSE:CVS) last posted its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. CVS Health’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is currently 74.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of CVS Health from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Wolfe Research increased their price target on shares of CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Jefferies Financial Group increased their price target on shares of CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 30th. Sanford C. Bernstein increased their price target on shares of CVS Health from $72.00 to $77.00 and gave the stock a “market perform” rating in a research note on Friday, September 5th. Finally, Zacks Research lowered shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $78.25.

Insider Transactions at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.22% of the stock is owned by corporate insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.